You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
現代中藥集團(01643.HK)2020年度純利升37.5%至6357.7萬元
格隆匯 03-26 22:08

格隆匯 3 月 26日丨現代中藥集團(01643.HK)公佈,截至2020年12月31日止年度,實現收益3.09億元(人民幣,下同),同比增長41.11%;毛利1.37億元,同比增長38.15%;純利6357.7萬元,同比增長37.50%;每股基本及攤薄盈利14.13分,董事會並不建議派付截至2020年12月31日止年度的任何股息。

集團主要從事生產中成藥,特別是在中國提供中老年人士使用的非處方藥及處方藥。集團目前擁有約60種中成藥產品,主要產品包括補腎填精丸、氣血雙補丸、山玫膠囊、金匱腎氣丸、心安膠囊、加味逍遙丸、護肝片、加味藿香正氣丸及清瘟解毒丸。

收益增加主要是由於銷售擁有治療2019新冠病毒病症及╱或相似病症目標療效的兩大產品(即加味藿香正氣丸及清瘟解毒丸)產生的收益激增所致。

集團目前已建立具有70多名分銷商組成的分銷網絡,覆蓋中國約40個城市,並由30多名具有傳統中醫藥行業相關經驗的市場推廣人員提供服務及管理。相信在可預見的未來,集團的分銷網絡及分銷商模式將繼續支援業務經營的進一步發展。此外,亦認為,分銷網絡不僅有助於將業務營運從東北擴張至中國其他地區,亦能讓集團頗為深入及廣泛地滲透東北,而由於集團在中國東北已建立覆蓋點及該地區人口龐大,當地成為集團的戰略目標。於2020年度,中國東北地區的收益貢獻約集團總收益的53.4%(2019年:約55.0%)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account